02:38 AM EDT, 09/14/2026 (MT Newswires) -- GSK's (GSK.L) licensor Hansoh Pharmaceutical Group outlined positive results from the late-stage study of its antibody-drug conjugate risvutatug rezetecan, or Ris-Rez, in patients with relapsed small cell lung cancer. The phase 3 ARTEMIS-008 trial, conducted in China, met its primary endpoint with the drug candidate reducing the risk of death by 54%, compared with topotecan, according to a Monday filing by the British drugmaker. Patients receiving Ris-Rez lived a median of 18.5 months, compared with 10.3 months for the patients receiving topotecan. The candidate's safety profile was also better than topoteca, with patients showing fewer severe treatment-related side effects.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.